National Pharmaceutical Pricing Authority, NPPA has revised the ceiling price of 883 scheduled formulations. The Authority in its meeting today noted with satisfaction that the supply disruption of active pharmaceutical ingredients caused by COVID-19 outbreak is returning to normalcy.

It said, no unusual price fluctuations in price of inputs for medicines, amid COVID-19 outbreak has been reported. Hence, normal price revisions have been allowed.

The WPI increase has been based on the data published by Department for Promotion of Industry and Internal Trade. Increase in ceiling price is based on Wholesale Price Index (WPI) which is 1.88468 percent.

The revision in ceiling price of formulations includes the revision of ceiling price of cardiac stents also. The revised prices will be applicable from tomorrow and the detail of revised prices is available on NPPA’s website www.nppaindia.nic.in.